Intersect Capital’s GSK GSK Stock Holding History

Intersect Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$427K	Buy	7,841 +2,920	+59%	+$161K	0.13%	173
2022 Q1	$268K	Buy	4,921 +653	+15%	+$35.5K	0.05%	338
2021 Q4	$235K	Buy	+4,268	New	+$222K	0.04%	370
2019 Q2	–	Sell	-3,845	Closed	-$201K	–	174
2019 Q1	$201K	Buy	+3,845	New	+$192K	0.08%	137
2017 Q4	–	Sell	-4,584	Closed	-$233K	–	117
2017 Q3	$233K	Hold	4,584	–	–	0.13%	104
2017 Q2	$247K	Buy	+4,584	New	+$244K	0.15%	95
2017 Q1	–	Sell	-4,184	Closed	-$201K	–	90
2016 Q4	$201K	Hold	4,184	–	–	0.15%	91
2016 Q3	$226K	Buy	+4,184	New	+$229K	0.18%	86
2016 Q1	–	Sell	-5,473	Closed	-$276K	–	112
2015 Q4	$276K	Sell	5,473 -80	-1%	-$4.08K	0.24%	77
2015 Q3	$267K	Sell	5,553 -800	-13%	-$41.6K	0.25%	77
2015 Q2	$331K	Hold	6,353	–	–	0.28%	65
2015 Q1	$366K	Buy	6,353 +1,024	+19%	+$58.7K	0.28%	61
2014 Q4	$285K	Buy	+5,329	New	+$298K	0.24%	68

Other funds holding GSK

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Parallax Volatility Advisers San Francisco, California $58.9B AUM 51.73% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Intersect Capital's GSK Position: Q2 2022 in Review

Intersect Capital increased its GSK (GSK) stake by 59% in Q2 2022, buying an estimated $161K and bringing the position to 7,841 shares worth $427K. The position accounts for 0.13% of the portfolio, ranked #173.

Intersect Capital first reported a position in GSK in Q4 2014 and has held it in 13 quarters since. 901 funds tracked by Wall St. Rank hold GSK as of Q2 2022.

Intersect Capital held 7,841 shares of GSK worth $427K as of Q2 2022.
Intersect Capital bought 2,920 GSK shares in Q2 2022, an estimated $161K.
GSK made up 0.13% of Intersect Capital's portfolio in Q2 2022, its #173 holding.
Intersect Capital first reported a position in GSK in Q4 2014 and has held it in 13 quarters since.
901 funds tracked by Wall St. Rank held GSK as of Q2 2022.

Based on Intersect Capital's 13F filing for Q2 2022, filed 2 Sep 2022.